1. Jo SH. N-acetylcysteine for prevention of contrast-induced nephropathy: a narrative review. Korean Circ J. 2011; 41:695–702. PMID:
22259598.
Article
2. Yun KH, Lim JH, Hwang KB, et al. Effect of high dose rosuvastatin loading before percutaneous coronary intervention on contrast-induced nephropathy. Korean Circ J. 2014; 44:301–306. PMID:
25278982.
Article
3. Almendarez M, Gurm HS, Mariani J Jr, et al. Procedural strategies to reduce the incidence of contrast-induced acute kidney injury during percutaneous coronary intervention. JACC Cardiovasc Interv. 2019; 12:1877–1888. PMID:
31521648.
4. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004; 44:1763–1771. PMID:
15519005.
Article
5. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005; 68:14–22. PMID:
15954892.
Article
6. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003; 348:491–499. PMID:
12571256.
Article
7. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006; 48:924–930. PMID:
16949481.
8. Seeliger E, Flemming B, Wronski T, et al. Viscosity of contrast media perturbs renal hemodynamics. J Am Soc Nephrol. 2007; 18:2912–2920. PMID:
17942967.
Article
9. Du M, Jiang L, Tang X, Gao Z, Xu B, Yuan J. Contrast induced nephropathy and 2-year outcomes of iso-osmolar compared with low-osmolar contrast media after elective percutaneous coronary intervention. Korean Circ J. 2021; 51:174–181. PMID:
33525073.
Article
10. Weisbord SD, Palevsky PM, Kaufman JS, et al. Contrast-associated acute kidney injury and serious adverse outcomes following angiography. J Am Coll Cardiol. 2020; 75:1311–1320. PMID:
32192658.